Rare disease CRO market seen reaching $3.16 billion by 2030

The rare disease contract research organization market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030 as gene and cell therapy pipelines, orphan drug activity and decentralized trials expand. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Rare disease CROs help drugmakers run clinical trials in small, hard-to-recruit patient populations. - The market is becoming more important as precision medicine, orphan drugs and gene and cell therapies need specialized trial support. - Faster trial execution could help bring rare disease treatments to patients sooner.

What happened: - The Business Research Company published its Global Market Report 2026 for the rare disease contract research organization market. - The report values the market at $2.07 billion in 2025 and projects $2.25 billion in 2026. - The report forecasts the market will reach $3.16 billion by 2030. - The report estimates a 8.6% CAGR from 2025 to 2026 and an 8.9% CAGR through 2030. - North America held the largest regional share in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the next several years.

The details: - Rare disease CROs support pharmaceutical and biotech companies with trial design and execution for rare or orphan diseases. - The model is designed for small patient populations and complex disease profiles. - Historical growth was constrained by limited rare disease awareness, fragmented clinical data systems, high orphan drug development costs, traditional site-based clinical models and inconsistent global regulatory frameworks. - The report says genomic sequencing, orphan drug approvals, precision medicine, decentralized clinical trials, better patient access and higher biotech investment are driving future growth. - The report highlights patient-centric trial designs for ultra-rare diseases, global patient registry networks, decentralized and hybrid trial models, orphan drug regulatory consulting and greater use of real-world evidence as key trends. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package also includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables. - A free sample is available here. - The full report is available here.

Between the lines: - The report points to a market shifting from niche support work to a more strategic role in drug development. - Gene and cell therapy pipelines appear to be a major demand driver because these programs require specialized recruitment, logistics and regulatory handling. - The growth outlook suggests rare disease research is moving toward more distributed and data-driven trial models. - The report also signals that regional growth may broaden beyond established North American leaders as biotech capacity expands in Asia-Pacific.

What's next: - The market is expected to keep expanding through 2030 as more orphan drugs and advanced therapies move into development. - Decentralized and hybrid trial models are likely to gain more traction as sponsors look for faster patient access and better enrollment. - Greater use of patient registries and real-world evidence is likely to shape trial design and validation work. - Biotech investment and regulatory consulting demand may rise alongside the next wave of rare disease programs.